| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Crescent Biopharma, Inc. (CBIO) has 9 insiders with recent SEC Form 4 filings, including 1 buy and 7 sells. CBIO is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 3.60M | $56.79M | +1.38M | |
| CEO | 180.5K | $2.85M | - | |
| COO | 78.0K | $1.23M | - | |
| Other | 54.2K | $854.6K | - | |
| Other | 17.5K | $276.1K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jul 6, 2016 | Thackray Helen M.78 | VP Clinical Development, CMO | Sell | 22,000 | $7.00 | $153,953.84 | -4.1% | |
| Mar 4, 2016 | Goldberg Mark Alan | Director | Buy | 10,397 | $4.77 | $49,630.08 | +945.2% | |
| Nov 16, 2015 | New Enterprise Associates 10 L P | 10% Owner | Sell | 452 | $6.91 | $3,123.32 | - | |
| Nov 16, 2015 | Barrett M James | Director, 10% Owner | Sell | 452 | $6.91 | $3,123.32 | - | |
| Nov 16, 2015 | Sandell Scott D55 | 10% Owner | Sell | 452 | $6.91 | $3,123.32 | - | |
| Nov 16, 2015 | Barris Peter J | 10% Owner | Sell | 452 | $6.91 | $3,123.32 | - |